Igm Biosciences Inc (IGMS)

$7.2

-0.21

(-2.83%)

Market is closed - opens 7 PM, 22 Apr 2024

Performance

  • $7.06
    $7.43
    $7.20
    downward going graph

    1.94%

    Downside

    Day's Volatility :4.98%

    Upside

    3.1%

    downward going graph
  • $3.81
    $17.70
    $7.20
    downward going graph

    47.08%

    Downside

    52 Weeks Volatility :78.47%

    Upside

    59.32%

    downward going graph

Returns

PeriodIgm Biosciences Inc
3 Months
-34.96%
6 Months
65.14%
1 Year
-33.33%
3 Years
-87.58%

Highlights

Market Capitalization
435.6M
Book Value
$3.46
Earnings Per Share (EPS)
-4.71
Wall Street Target Price
21.22
Profit Margin
0.0%
Operating Margin TTM
-9722.43%
Return On Assets TTM
-34.91%
Return On Equity TTM
-100.48%
Revenue TTM
2.1M
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
75.0%
Gross Profit TTM
1.1M
EBITDA
-253.4M
Diluted Eps TTM
-4.71
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.21
EPS Estimate Next Year
-2.88
EPS Estimate Current Quarter
-1.03
EPS Estimate Next Quarter
-0.94

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Igm Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
13
13
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 194.72%

Current $7.20
Target $21.22

Technicals Summary

Sell

Neutral

Buy

Igm Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Igm Biosciences Inc
Igm Biosciences Inc
-26.98%
65.14%
-33.33%
-87.58%
-70.37%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Igm Biosciences Inc
Igm Biosciences Inc
NA
NA
NA
-3.21
-1.0
-0.35
NA
3.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Igm Biosciences Inc
Igm Biosciences Inc
Buy
$435.6M
-70.37%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • Baker Bros Advisors LP

    6.28%
  • T. Rowe Price Associates, Inc.

    5.55%
  • Artal Group S A

    5.27%
  • Redmile Group, LLC

    5.05%
  • Goldman Sachs Group Inc

    3.54%
  • FMR Inc

    2.89%

Corporate Announcements

  • Igm Biosciences Inc Earnings

    Igm Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

igm biosciences, inc., a biotechnology company, engages in the research and development of immunoglobulin m (igm) antibodies for the treatment of cancer. the company's lead product candidate is igm-2323, a bispecific igm antibody that is in phase 1 clinical trials to treat patients with b cell nhl and other b cell malignancies. it is also developing igm-8444, an igm antibody targeting death receptor 5 proteins; and igm-7354, is a bispecific igm antibody delivering interleukin-15 cytokines to pd-l1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. igm biosciences, inc. has a collaboration with atreca inc. and beigene ltd. to discover, develop, and manufacture novel igm and iga antibodies targeting sars-cov-2 for the potential treatment of covid-19; and strategic research collaboration and license agreement with abcellera to discover and develop igm antibodies. the company was formerly known as palingen, inc. and changed its name to igm biosci

Organization
Igm Biosciences Inc
Employees
224
CEO
Mr. Fred M. Schwarzer J.D.
Industry
Health Technology

FAQs